By Mary Stuart
Published in the January 17, 2017 Issue (Vol. 4, No. 1)
SPR Therapeutics has developed a peripheral nerve stimulation therapy to address chronic pain syndromes in the back, limbs, and shoulder, as well as acute pain following joint replacement surgery. Delivered percutaneously for 30 days, the company’s FDA-cleared, single-use disposable PNS platform has the potential to revolutionize pain management, offering a device-based alternative to highly addictive opioid drugs.
SPR Therapeutics Inc.